Company news

BioCardia, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company’s Lead Cell Therapy for Treatment of Heart Failure

May 1, 2025

BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial

April 15, 2025

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

April 11, 2025

BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4: 30PM EDT Time Today

March 31, 2025

Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years

March 31, 2025

BioCardia Reports 2024 Business Highlights and Financial Results

March 26, 2025

BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

March 21, 2025

BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

March 10, 2025

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

February 27, 2025

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

February 12, 2025

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

January 26, 2025

BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family

December 16, 2024

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

December 3, 2024

BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results

November 12, 2024

BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024

November 5, 2024

BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure

October 27, 2024

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

September 17, 2024

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

September 8, 2024

BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

August 29, 2024

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

August 28, 2024

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

August 20, 2024

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

August 12, 2024

BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024

August 6, 2024

BioCardia Submits for FDA Approval of Morph® DNA™ Steerable Introducer Product Family

July 29, 2024

Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure

July 24, 2024

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

July 16, 2024

CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction

July 7, 2024

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach

June 6, 2024

BioCardia Announces Reverse Stock Split

May 20, 2024

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

May 13, 2024

BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024

May 8, 2024

BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

April 30, 2024

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

April 24, 2024

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

March 26, 2024

BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024

March 19, 2024

BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

March 12, 2024

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

March 11, 2024

BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

March 3, 2024

BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

February 7, 2024

BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference

January 30, 2024

BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders

January 2, 2024

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

December 18, 2023

BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes

December 17, 2023

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval

November 28, 2023

BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

November 15, 2023

BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

November 13, 2023

BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results

November 7, 2023

BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023

October 31, 2023

BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II

October 10, 2023

BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs

September 5, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 13 decks. Every deck is listed under its year.